BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200922
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T113630
CREATED:20200615T080459Z
LAST-MODIFIED:20200615T080459Z
UID:25926-1600732800-1600991999@www.pharmajournalist.com
SUMMARY:11th World Bispecific Summit – Running Virtually for 2020
DESCRIPTION:Transforming to a digital platform for the eleventh year\, the World Bispecific Summit will continue to deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational and manufacturing challenges faced in the bispecific field. Whatever your role and interest in the field\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 40+ expert speakers are\, and the topics they will examine\, including how: \n\nMacroGenics are evaluating selection and format optimization of bispecific molecules for a simultaneous blockade of PD-1 and LAG-3 (MGD013) versus PD-1 and CTLA4 (MGD019)\nSound Biologics are pioneering their unique platform\, MabPair Technology for making bi-functional antibody\nInvenra demonstrates preclinical efficacy through the selective elimination of tumor Tregs\nIncyte and Adimab are enhancing the selectivity of bispecific approaches to reduce on-target off-tumor toxicities in solid tumor indications\nGenentech are showcasing how several factors such as epitope\, binding affinity\, format\, target expression\, etc.\, influence the design and development of T-cell bispecific for cancer immunotherapy\n\nDownload the event guide to find out more
URL:https://www.pharmajournalist.com/event/11th-world-bispecific-summit-running-virtually-for-2020/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR